Label Stock Vendors Under Investigation

UPM-Kymmene counters that its label stock subsidiary, Raflatac, is a relatively small player in the U.S. label stock market.

The MACtac acquisition would allow Raflatac to introduce a full line of products in the U.S. and compete more efficiently. Even after the MACtac acquisition, Raflatac would only have a market share in America of approximately 15 percent, according to the company.